Messenger RNA COVID-19 vaccines induce high levels of short-lived antibodies compared to natural infection

In a recent study posted to the medRxiv* pre-print server, researchers extensively investigated the dynamics of antibodies induced by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination in Qatar's diverse population.

The researchers found that the two-dose vaccine regimen with a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine boosted antibody levels, albeit for a short time span.

Study: High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants. Image Credit: PIC SNIPE/Shutterstock
Study: High but Short-lived anti-SARS-CoV2 neutralizing, IgM, IgA, and IgG levels among mRNA-vaccinees compared to naturally-infected participants. Image Credit: PIC SNIPE/Shutterstock


A mass vaccination drive began in December 2020 in Qatar, and by February 2022, Qatar had fully vaccinated around 88% of its population over 12 years of age. Despite widespread vaccination, the country witnessed two COVID-19 waves due to SARS-CoV-2 Alpha, Beta, and Delta variants between January and June 2021.

Yet again, there was an unprecedented surge in the number of COVID-19 cases between December 2021 and January 2022. During this time, Qatar hit an all-time high number of new daily COVID-19 cases. During this time, their public health officials realized that protecting the vaccinated as well as naïve and naturally infected population against the new SARS-CoV-2 variants was tedious and needed immediate attention.

There is very little data to define an antibody titer threshold that is adequate to protect an individual from SARS-CoV-2 infection. Moreover, the United States Federal Food and Drug Administration (FDA) has not approved a single serology test, which may indicate whether a person is protected from COVID-19 or not. Overall, there is a dearth of evidence for SARS-CoV-2 infection-induced immunity compared to vaccine-induced immunity.

About the study

In the present study, researchers assessed the antibody responses of Qatar's population, focusing specifically on vaccination naïve (VN) and naturally infected (NI) individuals. Qatar used two FDA-approved mRNA-based vaccines, BNT162b2 and mRNA-1273, for their mass vaccination programs.

The 100 VN study participants had received a two-dose regimen of BNT162b2 or mRNA-1273. On the other hand, the NI group had 40 subjects who were unvaccinated but naturally infected at least once with COVID-19. The team collected phase I blood samples from the VN group at 1.4 months and phase II samples at 5.3 months after the second vaccine dose. For the NI group, the sample collection time points for phase I and phase II were ~1.7 months and 5.2 months, respectively, after contracting COVID-19.

The researchers used the plasma of all the study participants for serological testing. Additionally, prior to sample collection, the researchers gathered demographic and all COVID-19-related information from the study participants.

The team performed serology tests to determine the presence of SARS-CoV-2 neutralizing antibodies (nAbs) in the obtained samples. First, they detected nAbs with a World Health Organization (WHO) conversion factor of one arbitrary unit (AU)= 3.31 IU/mL. Next, they detected antibodies to the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein, anti-S-RBD-immunoglobulin G (IgG). It had a WHO standardization factor of 1.15 binding antibody units (BAU)/mL. Likewise, they assessed anti-S-RBD-IgM and anti-S1-IgA levels in serum samples from individuals of the VN and NI groups.

Further, the team used an architect automated chemiluminescent assay to test the samples for the previous infection. The assay detected SARS-CoV-2 anti-nucleoprotein (anti-N) IgG antibodies, and positive anti-N results indicated previous exposure to SARS-CoV-2. The team excluded such samples from the VN study group.

Regarding statistics, the researchers summarized all continuous variables using geometric mean titers (GMTs) and 95% confidence intervals (CIs). They made scatter plots on which the horizontal bar line and the error bar line showed the GMTs and 95% CIs, respectively.

Lastly, the team performed Wilcoxon rank-sum test for pairwise group comparisons and Mann-Whitney U to depict the variations between the independent samples. They also used the Shapiro–Wilk normality test to normalize the collected data.

Study findings

Compared to natural infection, mRNA vaccination elicited anti-S-RBD- IgG and anti-S1-IgA antibodies in significantly high amounts. Within 23 weeks, this boost in antibody levels diminished by two to six-fold. Although natural infection initially elicited anti-SARS-CoV-2 antibodies in lesser quantities they remained steady and declined by around one to two-fold 22-weeks post-SARS-CoV-2-infection. Notably, anti-S1-IgA levels initially were three-fold higher in the VN group than in the NI group, i.e., phase I. However, by the end of the follow-up period, anti-S1-IgA levels became similar in the two groups.

Previous studies have fetched similar results and demonstrated that IgA antibodies dominate the early immune response to SARS-CoV-2 in unvaccinated subjects. In fact, a recent report indicated that individuals having IgA antibodies never contract COVID-19, while individuals with both IgG antibodies and T cells contract the infection. It is worth noting that IgA antibodies against SARS-CoV-2 S antigens persist for around three months in salivary and nasal secretions. Therefore, it is important to assess anti-S1-IgA antibodies after vaccination, just like IgG and IgM antibodies.


According to the authors, it is the first-ever study to comprehensively evaluate the levels of anti-S1-IgA antibodies in vaccinated individuals, along with anti-S-RBD-IgG and anti-S-RBD-IgM levels. The study findings demonstrated the extent of the waning of each anti-SARS-CoV-2 nAb, which could help policymakers make informed decisions regarding vaccination strategies.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2022, May 12). Messenger RNA COVID-19 vaccines induce high levels of short-lived antibodies compared to natural infection. News-Medical. Retrieved on December 07, 2022 from

  • MLA

    Mathur, Neha. "Messenger RNA COVID-19 vaccines induce high levels of short-lived antibodies compared to natural infection". News-Medical. 07 December 2022. <>.

  • Chicago

    Mathur, Neha. "Messenger RNA COVID-19 vaccines induce high levels of short-lived antibodies compared to natural infection". News-Medical. (accessed December 07, 2022).

  • Harvard

    Mathur, Neha. 2022. Messenger RNA COVID-19 vaccines induce high levels of short-lived antibodies compared to natural infection. News-Medical, viewed 07 December 2022,


  1. Tom Flaherty Tom Flaherty United States says:

    Thank You Neha,

    The data was helpfully easy for a non med guy to get.  For the longest time I have wondered about individuals without tonsils.  A friend  calls them the palace guards and knowing they may be the largest BProducing nodes and placed so high and close to source  infections I worry Covid could anchor more severely  and the immune  response  be less robust.  Many Americans my age don't have the tonsils.  A comparison of halves and have nots would be interesting.

    Thank You Again for efforts in the quest of knowledge and wellbeing.

  2. Michael B Michael B United States says:

    This article features a terrible headline that seems tailored to mislead people into believing that humoral specificity acquired through exposure is somehow superior to that acquired through vaccination.  Nearly every person that has died from Covid-19 has died as a consequence--at least partially--of infection derived antibody dependent processes.

    Not every antibody is your friend.  This is particularly true with SARS, MERS, SARS-CoV-2, and Omicron all of which trigger MASP-2 mediated Complement Hyperactivation when the Nucleocapsid is exposed to extracellular space.  The processes responsible for this exposure--the lytic Complement responses--are largely reliant upon immune complex signaling to establish locations on viral surfaces for Convertase assembly. Vaccination with Spike antigen only vaccines discourages this process by training an immune response that focuses on neutralization and phagocytosis rather than direct lysis of the SARS-CoV-2 virion, and the pathogenic downstream processes that follow.  This discouragement occurs explicitly because vaccinees produce a paucity of the M-protein specific antibodies that trigger the Classical Pathway of Complement.  The same is not true of vaccine naive SARS-CoV-2 carriers, they produce M-protein specific antibodies in accordance to the ratio at which they are initially presented to B-cells, follicular or otherwise.

    The real question, as far as this headline is concerned, is why is the antibody response resulting from infection so durable?  It is durable for the same reason the antibody responses to HIV, EBV, and Hepatitis C are durable--metabolically active virus is being secreted into extracellular spaces months after seroconversion, triggering the production of antibodies in exposure dependent manner. These people aren't better protected, they're chronically infected with a virus they are unable to clear.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Are medical masks non-inferior to N95 respirators to prevent COVID-19 in health care workers providing routine care?